News

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...
In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...
Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...
Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic ...
The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.
Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...
Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...
Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.
GLP-1's, which are traditionally diabetes medications, have exploded in popularity since they were approved for weight-loss.
The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.